Pfizer (PFE, $54.95) study suggests 89% efficacy of COVID-19 drug in preventing hospitalizations
Pfizer said final analysis of its antiviral Covid-19 pill reveals almost 90% efficacy in preventing hospitalizations and deaths among high-risk patients.
In a final study data, Pfizer said its Paxlovid treatment remained 89% effective in preventing hospitalizations in high-risk unvaccinated people when used within three days of the appearance of symptoms.
However, a separate study suggested that the drug failed to meet the primary objective of reducing self-reported symptoms in 673 adults at standard risk of developing Covid-19 complications, Pfizer said. But the drug showed a trend toward reducing hospitalizations in the group by 70%.
PFE sees its Stochastic Oscillator recovers from oversold territory
On May 14, 2026, the Stochastic Oscillator for PFE moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .
PFE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
PFE moved below its 50-day moving average on April 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PFE crossed bearishly below the 50-day moving average on April 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for PFE entered a downward trend on May 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.629) is normal, around the industry mean (9.072). P/E Ratio (19.656) is within average values for comparable stocks, (20.323). Projected Growth (PEG Ratio) (13.773) is also within normal values, averaging (7.294). PFE's Dividend Yield (0.067) is considerably higher than the industry average of (0.028). P/S Ratio (2.326) is also within normal values, averaging (3.662).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement